Inotek Pharmaceuticals

Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

Retrieved on: 
Wednesday, October 4, 2023
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Constellation, Bachelor of Science, PTC Therapeutics, University, University of London, Therapy, MorphoSys, South African Institute of Chartered Accountants, Cardiovascular disease, Parexel, Bristol Myers Squibb, Sale, Editas Medicine, PDE9, Inotek Pharmaceuticals, Novartis, Patient, Trustee, Risk, Imperial College London, Merck, Ca2+/calmodulin-dependent protein kinase II, Pharmaceutical industry

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.
  • Ms. Reeve brings to Cardurion more than 25 years of global financial leadership and board experience across pharmaceutical, medical device and biopharma companies.
  • As a seasoned life sciences executive with deep expertise in finance, capital markets and corporate strategy, Emma brings tremendous perspective to Cardurion’s Board,” said Michael E. Mendelsohn, M.D., Founder and Chairman of Cardurion.
  • “I am impressed with the bold and innovative approach Cardurion is taking to help patients suffering from and at risk for cardiovascular disease,” said Ms. Reeve.

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

Retrieved on: 
Tuesday, September 12, 2023
GSK, Tuck School of Business, PTC Therapeutics, Therapy, Lehman Brothers, Rice University, Syneos Health, Biotechnology, PTC, Business, Human Genome Sciences, Dartmouth College, History, CNS, Inotek Pharmaceuticals, Acquisition, Nature, Drug discovery, HGSI, Economics, Pharmaceutical industry, Sensorium

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.

Key Points: 
  • BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.
  • “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium.
  • “He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages.
  • in economics and managerial studies from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College.

Catalent Announces Changes to its Board of Directors

Retrieved on: 
Monday, December 19, 2022
Health, Chemicals, Plastics, Manufacturing, Other Science, Science, Pharmaceutical, Biotechnology, Boehringer Ingelheim, Patient, Female, Merck, NYSE, Head, Information, Health, Leonard Green, Esperies, Growth, Retirement, COVID-19, CDMO, Failure, Mallinckrodt, Excipient, Therapy, Partner, CTLT, Acquisition, Leonard Green & Partners, Esperion Therapeutics, Fine chemical, Risk management, Pharmaceutical industry, Catalent, Inotek Pharmaceuticals

“On behalf of the Catalent Board of Directors and the entire company, I want to thank John for his leadership and countless contributions to our mission to help people live better and healthier lives,” said Mr. Carroll.

Key Points: 
  • “On behalf of the Catalent Board of Directors and the entire company, I want to thank John for his leadership and countless contributions to our mission to help people live better and healthier lives,” said Mr. Carroll.
  • “Rolf was a highly valued member of our board for the last eight years, and his guidance and deep industry insights have proven invaluable to Catalent’s leadership and his fellow board members.
  • Mr. Carroll has served on Catalent’s board since July 2015 and has been its lead independent director since October 2021.
  • Mr. Carroll has been chairperson of the board of directors of Esperion Therapeutics since June 2022.

Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Pharmaceutical, Health, Doctor of Philosophy, R, Endocytosis, Biophysics, CEO, AMAG Pharmaceuticals, ATACS, Inotek Pharmaceuticals, Pharmacokinetics, Biomedical engineering, Proteome, Epix Pharmaceuticals, LinkedIn, Growth, Protein, Duke University, University, NASDAQ, Anatomical terms of motion, Twitter, Patient, Biomedicine, University of California, San Diego, Multimedia, ATAC, Therapy, Engineering, Sale, Fine chemical

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer.
  • In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions.
  • View the full release here: https://www.businesswire.com/news/home/20220615005091/en/
    We are excited to welcome Adam to the Avilar leadership team during this time of significant growth of our company, said Daniel Grau, CEO and President of Avilar Therapeutics.
  • Dr. Muzikant joins Avilar after serving as Chief Business Officer of Flexion Therapeutics (NASDAQ: FLXN), where he was instrumental in the sale of the company to Pacira BioSciences for up to $1B in enterprise value.

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

Retrieved on: 
Wednesday, June 1, 2022
Leadership, Cholesterol, Board of directors, ESPR, Chairperson, Tablet, Air force, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Bempedoic acid, Ezetimibe, Growth, GLOBE, Patient, ANN, Health, COVID-19, NASDAQ, United, Twitter, Accredo, Board, Merck, Catalent, Merck & Co., Pharmaceutical industry, Inotek Pharmaceuticals, Esperies

ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperions Board of Directors.

Key Points: 
  • ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperions Board of Directors.
  • Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders.
  • "On behalf of the Esperion team and our directors, I am excited to welcome Marty as Chairperson of the Esperion Board.
  • In addition, Mr. Carroll has served on a number of Board of Directors beginning with Accredo Health in 2004.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

Retrieved on: 
Wednesday, August 4, 2021
Inotek Pharmaceuticals, Companies, Aerie Pharmaceuticals

WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.

Key Points: 
  • WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.
  • A pre-recorded presentation will be made available beginning Tuesday, August 17, 2021 at 7:00 a.m.
  • To access a webcast and subsequent archived recording of the H.C. Wainwright podium presentation, please visit Events in the Investors section of the Kala website at http://kalarx.com .
  • Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

Retrieved on: 
Thursday, July 29, 2021
Inotek Pharmaceuticals, Companies

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m.
  • The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 3852499.
  • Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.

PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15

Retrieved on: 
Wednesday, June 30, 2021
Health, Other Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Companies, Inotek Pharmaceuticals, Economy of the United States, Aerie Pharmaceuticals

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm 1:45 pm EDT.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm 1:45 pm EDT.
  • The event will be available via live webcast from the Events and Presentations page of the Investors section of the companys website at www.phasebio.com .
  • The webcast replay will be available for 90 days after the conclusion of the live presentation.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases.

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Pharmaceutical, Health, Companies, Inotek Pharmaceuticals

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference.

Key Points: 
  • Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference.
  • Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET.
  • The Company also has a pipeline of preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
  • For more information on Kala, please visit www.kalarx.com .

PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, Companies, Inotek Pharmaceuticals, Aerie Pharmaceuticals

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:00am ET.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:00am ET.
  • Interested parties can access the live and archived webcast of the event on the Events and Presentations page of the Investors section of the companys website at www.phasebio.com .
  • The webcast replay will be available for 90 days after the conclusion of the live presentation.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases.